According to a paper authored by the lab, the DeepSeek-R1 model outperforms cutting-edge models such as OpenAI’s o1 and ...

This article summarizes the most significant insider buying and selling activities reported on Friday for US-listed companies ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

We recently published an article titled Top 10 Health Information Services Stocks Outpacing The Market In 2025. In this ...

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...

Refusing to slow down since the start of the new year, shares of Tempus AI (NASDAQ: TEM) have skyrocketed nearly 99% since ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

On Wednesday, TD Cowen reiterated its buy rating for Tempus AI’s shares, while increasing the price target to $74 after the company successfully closed its acquisition of Ambry Genetics ...

with their view now clearly much more bullish on the company's business prospects. Tempus AI has also found favour with investors, with the stock up a remarkable 11% to US$68.36 over the past week.

In fact, “Ark Invest's interest in TEM began on December 6, when the ARK Genomic Revolution ETF made its initial purchase of shares in the healthcare technology company. Since then, Tempus AI ...